Publications by authors named "G Marsili"
Between August and 28 October 2024, 199 autochthonous cases of dengue virus serotype 2 were notified in the city of Fano, central Italy. We describe the ongoing epidemiological and microbiological investigation and public health measures implemented to contain the outbreak. The high transmissibility and the extension of the outbreak suggest that dengue should be expected in temperate regions during favourable seasons, highlighting the need for heightened awareness among healthcare providers and the public to ensure timely detection and response.
View Article and Find Full Text PDFArticle Synopsis
- In the past decade, targeted kidney inhibitors (TKIs) have significantly improved the survival rates of chronic myeloid leukemia (CML) patients, particularly those achieving deep and sustained molecular response (DMR), allowing some to consider stopping treatment.
- A study analyzed responses from 1,777 CML patients in Italy, focusing on the impact of different TKIs (imatinib, dasatinib, nilotinib) and timing of responses (3, 6, and 12 months).
- Results showed that patients achieving certain molecular response benchmarks at 3 months were more likely to achieve DMR later, with significant differences in outcomes based on the specific TKI used.
Article Synopsis
- ATRA and ATO are the main treatments for low to medium risk acute promyelocytic leukaemia (APL), but many patients (60%) can have a side effect called leucocytosis, which means very high white blood cell counts.
- Researchers studied 65 APL patients and found that those with lower levels of important blood proteins (like fibrinogen) and higher amounts of cancer cells in their bone marrow were more likely to have leucocytosis when treated with ATRA and ATO.
- Leucocytosis can lead to other serious problems, so doctors need to keep a close eye on patients with these risk factors to help prevent issues and give extra treatments if needed.
Arboviruses are pathogens transmitted mainly by mosquitoes, ticks, and sandflies [...
View Article and Find Full Text PDFWe analyzed 140 patients with a median age of 51 years; 21% had WBC ≥ 100 × 10/L, and 52% had an NPM1 co-mutation. Until 2018, 101 patients received chemotherapy; thereafter, 39 received 3+7+midostaurin. The overall CR rate was 64%, higher in NPM1 mutant patients (73%).
View Article and Find Full Text PDF